Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.550
+0.020 (0.57%)
Oct 30, 2026, 12:55 PM EDT - Market open
Molecular Partners AG Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
134
Market Cap
139.39M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
| Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
| Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
| Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
| Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
| Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
| Dec 31, 2018 | 10.36M | -9.66M | -48.27% |
| Dec 31, 2017 | 20.02M | -3.02M | -13.13% |
| Dec 31, 2016 | 23.04M | -6.08M | -20.88% |
| Dec 31, 2015 | 29.12M | 2.49M | 9.37% |
| Dec 31, 2014 | 26.63M | -5.79M | -17.87% |
| Dec 31, 2013 | 32.42M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Codexis | 77.68M |
| Atrium Therapeutics | 35.84M |
| Upstream Bio | 3.16M |
| Veraxa Biotech AG | 29.54K |
MOLN News
- 1 day ago - Molecular Partners AG Announces Strategic Shift to Radiopharmaceuticals and Intends to Reduce Workforce by No More Than 55 Positions - Nasdaq
- 1 day ago - Molecular Partners AG Earnings release: Q3 2026 - Filings
- 1 day ago - Molecular Partners AG Slides: Q3 2026 - Filings
- 1 day ago - Swiss biotech firm Molecular Partners to cut nearly half of workforce - Reuters
- 1 day ago - Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy - GlobeNewsWire
- 8 days ago - Molecular Partners selects MP0730 as lead Radio-DARPin candidate - TheFly
- 7 weeks ago - Clear Street transfers coverage on Molecular Partners, keeps Buy rating - TheFly
- 2 months ago - Molecular Partners AG Slides: Q2 2026 - Filings